ESOC 2023 | INTERACT3 helps to bridge the evidence-practice gap in intracerebral hemorrhage

INTERACT3 (NCT03209258), the largest clinical trial on intracerebral hemorrhage (ICH), has the potential to change clinical practice, having demonstrated a statistically significant improvement in functional outcomes with the use of a goal-directed care bundle for rapid correction of abnormal physiological variables, compared to usual care. Craig Anderson, PhD, from The George Institute for Global Health, describes how INTERACT3 studied patients with varying degrees of stroke severity, including those traditionally difficult to recruit due to their critical condition and high priority for surgery. This diversity in patient selection makes the trial’s results highly generalizable. The trial focuses on implementing changes in care systems, bridging the evidence-practice gap. It addressed critical aspects such as funding, training, and logistical considerations, making it more practical to adopt and sustain the care bundle protocol in a healthcare setting. Formative interviews with healthcare providers participating in the intervention rollout were conducted to assess successes and challenges, helping to ensure INTERACT3’s effectiveness. This interview took place at The European Stroke Organisation Conference 2023 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.